Field efficacy and safety of a novel oral chewable tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™) against naturally acquired gastrointestinal nematode infections in dogs presented as veterinary patients in Europe and the USA

Table 2 Efficacy of a single oral dose of Simparica Trio™ against natural nematode infections in dogs presented as veterinary patients in Europe

Nematode species	Sample^a	Treatment group^b	n	Egg count per gram feces			Efficacy
Nematode species	Sample^a	Treatment group^b	n	Geometric mean	95% CI	% Reduction	Test statistic^c
Across all species	Pre-treatment	Simparica Trio™	193	93.0	68.4–126.3
	Pre-treatment	Afox+Milb	97	108.1	73.2–159.4
	Post-treatment	Simparica Trio™	179	1.0	0.5–1.7	98.9	t_(17.9)= 22.11, P < 0.0001
	Post-treatment	Afox+Milb	91	1.4	0.7–2.4	98.7	t₍₅₉₎= 16.49, P < 0.0001
T. canis	Pre-treatment	Simparica Trio™	138	84.5	58.6–121.6	–
	Pre-treatment	Afox+Milb	62	104.8	63.0–173.9	–
	Post-treatment	Simparica Trio™	127	0.8	0.4–1.5	99.0	t₍₁₉₃₎= 19.97, P < 0.0001
	Post-treatment	Afox+Milb	56	0.7	0.2–1.6	99.3	t₍₁₉₄₎= 14.29, P < 0.0001
T. leonina	Pre-treatment	Simparica Trio™	9	18.6	6.9–47.9	–
	Pre-treatment	Afox+Milb	7	140.0	49.1–395.8	–
	Post-treatment	Simparica Trio™	9	0.3	− 0.2–1.2	98.3	t₍₁₄₎= 6.30, P < 0.0001
	Post-treatment	Afox+Milb	7	0.1	− 0.4–0.9	99.9	t₍₁₄₎= 9.98, P < 0.0001
A. caninum	Pre-treatment	Simparica Trio™	52	45.3	27.6–74.1	–
	Pre-treatment	Afox+Milb	28	49.3	26.7–90.2	–
	Post-treatment	Simparica Trio™	49	0.5	− 0.1–1.3	99.0	t_(28.8)= 11.21, P < 0.0001
	Post-treatment	Afox+Milb	28	1.3	0.3–2.8	97.4	t_(47.4)= 8.31, P < 0.0001
U. stenocephala	Pre-treatment	Simparica Trio™	23	86.9	32.8–227.6	–
	Pre-treatment	Afox+Milb	13	106.3	38.5–290.5	–
	Post-treatment	Simparica Trio™	22	0.3	− 0.5–2.3	99.7	t_(20.9)= 14.60, P < 0.0001
	Post-treatment	Afox+Milb	13	1.8	0.0–6.5	98.3	t₍₁₂₎= 5.87, P < 0.0001

^aPre-treatment sample collected once between Day-7 and 0; post-treatment sample collected between Day 7 and 14
^bSingle oral administration of Simparica Trio™ on Day 0 to provide dose ranges of 1.2–2.4 mg/kg sarolaner, 24–48 µg/kg moxidectin and 5–10 mg/kg pyrantel (as pamoate salt)
^cTest statistic and P-value for difference (pre-treatment – post-treatment) within group
Abbreviations: Afox, afoxolaner; Milb, milbemycin oxime; CI, confidence interval

ISSN: 1756-3305